TY - JOUR
T1 - Mechanical thrombectomy with retrievable stents and aspiration catheters for acute ischaemic stroke
T2 - a meta-analysis of randomised controlled trials
AU - Rajkumar, Christopher A.
AU - Ganesananthan, Sashiananthan
AU - Ahmad, Yousif
AU - Seligman, Henry
AU - Thornton, George D.
AU - Foley, Michael
AU - Nowbar, Alexandra N.
AU - Howard, James P.
AU - Francis, Darrel P.
AU - Keeble, Thomas R.
AU - Grunwald, Iris Q.
AU - Al-Lamee, Rasha K.
AU - Malik, Iqbal S.
AU - Shun-Shin, Matthew J.
N1 - Funding Information:
I. Grunwald is a co-founder and a shareholder of Brainomix. R. Al-Lamee reports speakers’ honoraria from Philips Volcano and Menarini Pharmaceuticals. H. Seligman declares research funding from Amgen. The other authors have no conflicts of interest to declare.
Funding Information:
C. Rajkumar is a PhD Training Fellow at the Medical Research Council [Grant Number MR/S021108/1]. M. Foley is a PhD Training Fellow at the Medical Research Council [Grant Number MR/V001620/1]. J.P. Howard is a PhD Training Fellow at the Wellcome Trust [Grant number 212183/Z/18/Z]. A. Nowbar is supported by the NIHR Imperial Biomedical Research Centre (BRC).
Publisher Copyright:
© Europa Digital & Publishing 2022. All rights reserved.
PY - 2022/4
Y1 - 2022/4
N2 - BACKGROUND: Retrievable stents and aspiration catheters have been developed to provide more effective arterial recanalisation in acute ischaemic stroke. AIMS: The aim of this analysis was to test the effect of mechanical thrombectomy on mortality and long-term neurological outcome in patients presenting with acute large-vessel anterior circulation ischaemic stroke. METHODS: A structured search identified randomised controlled trials of thrombectomy (using a retrievable stent or aspiration catheter) versus control on a background of medical therapy which included intravenous thrombolysis if appropriate. The primary endpoint was disability at 90-day follow-up as assessed by the modified Rankin scale (mRS). Secondary endpoints included all-cause mortality and symptomatic intracranial haemorrhage. A Bayesian mixed-effects model was used for analysis. RESULTS: Twelve trials met the inclusion criteria, comprising a total of 1,276 patients randomised to thrombectomy and 1,282 patients to control. Randomisation to thrombectomy significantly reduced disability at 90 days (odds ratio [OR] 0.52, 95% credible interval [CrI] 0.46 to 0.61, probability(control better)<0.0001). Furthermore, thrombectomy reduced the odds of functional dependence at 90 days, indicated by an mRS score >2 (OR 0.44, CrI 0.37 to 0.52, p<0.0001). Thrombectomy reduced all-cause mortality at 90 days (16.1% vs 19.2%, OR 0.81, 95% CrI 0.66 to 0.99, p=0.024). The frequency of symptomatic intracranial haemorrhage was similar between thrombectomy (4.2%) and control (4.0%) (OR 1.12, 95% CrI 0.76 to 1.68, p=0.72). CONCLUSIONS: In patients with an acute anterior circulation stroke, modern device thrombectomy significantly reduces death and subsequent disability. The magnitude of these effects suggests that universal access to this treatment strategy should be the standard of care.
AB - BACKGROUND: Retrievable stents and aspiration catheters have been developed to provide more effective arterial recanalisation in acute ischaemic stroke. AIMS: The aim of this analysis was to test the effect of mechanical thrombectomy on mortality and long-term neurological outcome in patients presenting with acute large-vessel anterior circulation ischaemic stroke. METHODS: A structured search identified randomised controlled trials of thrombectomy (using a retrievable stent or aspiration catheter) versus control on a background of medical therapy which included intravenous thrombolysis if appropriate. The primary endpoint was disability at 90-day follow-up as assessed by the modified Rankin scale (mRS). Secondary endpoints included all-cause mortality and symptomatic intracranial haemorrhage. A Bayesian mixed-effects model was used for analysis. RESULTS: Twelve trials met the inclusion criteria, comprising a total of 1,276 patients randomised to thrombectomy and 1,282 patients to control. Randomisation to thrombectomy significantly reduced disability at 90 days (odds ratio [OR] 0.52, 95% credible interval [CrI] 0.46 to 0.61, probability(control better)<0.0001). Furthermore, thrombectomy reduced the odds of functional dependence at 90 days, indicated by an mRS score >2 (OR 0.44, CrI 0.37 to 0.52, p<0.0001). Thrombectomy reduced all-cause mortality at 90 days (16.1% vs 19.2%, OR 0.81, 95% CrI 0.66 to 0.99, p=0.024). The frequency of symptomatic intracranial haemorrhage was similar between thrombectomy (4.2%) and control (4.0%) (OR 1.12, 95% CrI 0.76 to 1.68, p=0.72). CONCLUSIONS: In patients with an acute anterior circulation stroke, modern device thrombectomy significantly reduces death and subsequent disability. The magnitude of these effects suggests that universal access to this treatment strategy should be the standard of care.
KW - ischaemic stroke
KW - Stent retrievers
KW - thrombectomy
UR - http://www.scopus.com/inward/record.url?scp=85119039124&partnerID=8YFLogxK
U2 - 10.4244/EIJ-D-21-00343
DO - 10.4244/EIJ-D-21-00343
M3 - Article
C2 - 34503942
SN - 1774-024X
VL - 17
SP - e1425-e1434
JO - EuroIntervention
JF - EuroIntervention
IS - 17
ER -